These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 34259899)

  • 1. Prognostic impact of molecular muscle-invasive bladder cancer subtyping approaches and correlations with variant histology in a population-based mono-institutional cystectomy cohort.
    Weyerer V; Stoehr R; Bertz S; Lange F; Geppert CI; Wach S; Taubert H; Sikic D; Wullich B; Hartmann A; Eckstein M
    World J Urol; 2021 Nov; 39(11):4011-4019. PubMed ID: 34259899
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of immunohistochemistry-based subtyping of GATA3, CK20, CK5/6, and CK14 expression on survival after radical cystectomy for muscle-invasive bladder cancer.
    Bejrananda T; Kanjanapradit K; Saetang J; Sangkhathat S
    Sci Rep; 2021 Oct; 11(1):21186. PubMed ID: 34707176
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CK5/6 and GATA3 Defined Phenotypes of Muscle-Invasive Bladder Cancer: Impact in Adjuvant Chemotherapy and Molecular Subtyping of Negative Cases.
    Koll FJ; Schwarz A; Köllermann J; Banek S; Kluth L; Wittler C; Bankov K; Döring C; Becker N; Chun FKH; Wild PJ; Reis H
    Front Med (Lausanne); 2022; 9():875142. PubMed ID: 35783619
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predicting outcomes in non-muscle invasive (Ta/T1) bladder cancer: the role of molecular grade based on luminal/basal phenotype.
    Rebola J; Aguiar P; Blanca A; Montironi R; Cimadamore A; Cheng L; Henriques V; Lobato-Faria P; Lopez-Beltran A
    Virchows Arch; 2019 Oct; 475(4):445-455. PubMed ID: 31240474
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Different Responses to Neoadjuvant Chemotherapy in Urothelial Carcinoma Molecular Subtypes.
    Sjödahl G; Abrahamsson J; Holmsten K; Bernardo C; Chebil G; Eriksson P; Johansson I; Kollberg P; Lindh C; Lövgren K; Marzouka NA; Olsson H; Höglund M; Ullén A; Liedberg F
    Eur Urol; 2022 May; 81(5):523-532. PubMed ID: 34782206
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical Parameters Outperform Molecular Subtypes for Predicting Outcome in Bladder Cancer: Results from Multiple Cohorts, Including TCGA.
    Morera DS; Hasanali SL; Belew D; Ghosh S; Klaassen Z; Jordan AR; Wang J; Terris MK; Bollag RJ; Merseburger AS; Stenzl A; Soloway MS; Lokeshwar VB
    J Urol; 2020 Jan; 203(1):62-72. PubMed ID: 31112107
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic stratification of muscle invasive urothelial carcinomas using limited immunohistochemical panel of Gata3 and cytokeratins 5/6, 14 and 20.
    Jangir H; Nambirajan A; Seth A; Sahoo RK; Dinda AK; Nayak B; Kaushal S
    Ann Diagn Pathol; 2019 Dec; 43():151397. PubMed ID: 31494492
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FOXA1 and CK14 as markers of luminal and basal subtypes in histologic variants of bladder cancer and their associated conventional urothelial carcinoma.
    Warrick JI; Kaag M; Raman JD; Chan W; Tran T; Kunchala S; Shuman L; DeGraff D; Chen G
    Virchows Arch; 2017 Sep; 471(3):337-345. PubMed ID: 28721490
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gene Expression Profiling of Muscle-Invasive Bladder Cancer With Secondary Variant Histology.
    de Jong JJ; Narayan VM; Cronican AA; Gupta S; van Leenders GJLH; Boormans JL; Gibb EA; Konety BR
    Am J Clin Pathol; 2021 Oct; 156(5):895-905. PubMed ID: 34157072
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular Subtyping of Clinically Localized Urothelial Carcinoma Reveals Lower Rates of Pathological Upstaging at Radical Cystectomy Among Luminal Tumors.
    Lotan Y; Boorjian SA; Zhang J; Bivalacqua TJ; Porten SP; Wheeler T; Lerner SP; Hutchinson R; Francis F; Davicioni E; Svatek RS; Chen CL; Black PC; Gibb EA
    Eur Urol; 2019 Aug; 76(2):200-206. PubMed ID: 31092337
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lymphovascular invasion, ureteral reimplantation and prior history of urothelial carcinoma are associated with poor prognosis after partial cystectomy for muscle-invasive bladder cancer with negative pelvic lymph nodes.
    Ma B; Li H; Zhang C; Yang K; Qiao B; Zhang Z; Xu Y
    Eur J Surg Oncol; 2013 Oct; 39(10):1150-6. PubMed ID: 23721764
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nested Variant of Urothelial Carcinoma Is a Luminal Bladder Tumor With Distinct Coexpression of the Basal Marker Cytokeratin 5/6.
    Johnson SM; Khararjian A; Legesse TB; Khani F; Robinson BD; Epstein JI; Wobker SE
    Am J Clin Pathol; 2021 Mar; 155(4):588-596. PubMed ID: 33118597
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Prognostic Gene Expression Signature in the Molecular Classification of Chemotherapy-naïve Urothelial Cancer is Predictive of Clinical Outcomes from Neoadjuvant Chemotherapy: A Phase 2 Trial of Dose-dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin with Bevacizumab in Urothelial Cancer.
    McConkey DJ; Choi W; Shen Y; Lee IL; Porten S; Matin SF; Kamat AM; Corn P; Millikan RE; Dinney C; Czerniak B; Siefker-Radtke AO
    Eur Urol; 2016 May; 69(5):855-62. PubMed ID: 26343003
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The impact of histological reclassification during pathology re-review--evidence of a Will Rogers effect in bladder cancer?
    Linder BJ; Boorjian SA; Cheville JC; Sukov WR; Thapa P; Tarrell RF; Frank I
    J Urol; 2013 Nov; 190(5):1692-6. PubMed ID: 23707452
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Greater utility of molecular subtype rather than epithelial-to-mesenchymal transition (EMT) markers for prognosis in high-risk non-muscle-invasive (HGT1) bladder cancer.
    Ottley EC; Pell R; Brazier B; Hollidge J; Kartsonaki C; Browning L; O'Neill E; Kiltie AE
    J Pathol Clin Res; 2020 Oct; 6(4):238-251. PubMed ID: 32374509
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of Molecular Subtyping and Immune Infiltration on Pathological Response and Outcome Following Neoadjuvant Pembrolizumab in Muscle-invasive Bladder Cancer.
    Necchi A; Raggi D; Gallina A; Ross JS; Farè E; Giannatempo P; Marandino L; Colecchia M; Lucianò R; Bianchi M; Colombo R; Salonia A; Gandaglia G; Fossati N; Bandini M; Pederzoli F; Capitanio U; Montorsi F; de Jong JJ; Dittamore R; Liu Y; Davicioni E; Boormans JL; Briganti A; Black PC; Gibb EA
    Eur Urol; 2020 Jun; 77(6):701-710. PubMed ID: 32165065
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The impact of squamous and glandular differentiation on survival after radical cystectomy for urothelial carcinoma.
    Kim SP; Frank I; Cheville JC; Thompson RH; Weight CJ; Thapa P; Boorjian SA
    J Urol; 2012 Aug; 188(2):405-9. PubMed ID: 22704101
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sensitivity of initial biopsy or transurethral resection of bladder tumor(s) for detecting histological variants on radical cystectomy.
    Ge P; Wang ZC; Yu X; Lin J; He Q
    BMC Urol; 2015 May; 15():46. PubMed ID: 26025446
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alignment of molecular subtypes across multiple bladder cancer subtyping classifiers.
    Reike MJ; de Jong JJ; Bismar TA; Boorjian SA; Mian OY; Wright JL; Dall'Era MA; Kaimakliotis HZ; Lotan Y; Boormans JL; Black PC; Gibb EA
    Urol Oncol; 2024 Jun; 42(6):177.e5-177.e14. PubMed ID: 38480079
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pathological characteristics and prognostic indicators of different histopathological types of urinary bladder cancer following radical cystectomy in a large single-center Egyptian cohort.
    Martin JW; Vernez SL; Lotan Y; Abdelhalim A; Dutta R; Shokeir A; Abol-Enein H; Mosbah A; Ghoneim M; Youssef RF
    World J Urol; 2018 Nov; 36(11):1835-1843. PubMed ID: 29761225
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.